MAPK-IN-1

• CAT Number: I043561
• CAS Number: 2470587-69-8
• Molecular Formula: C19H18O4
• Molecular Weight: 310.34
• Purity: ≥95%
• Synonyms: (1R)-1,6,6-trimethyl-1,2,8,9-tetrahydronaphtho[1,2-g][1]benzofuran-7,10,11-trione
• InChI: InChI=1S/C19H18O4/c1-9-8-23-18-11-4-6-12-10(5-7-13(20)19(12,2)3)15(11)17(22)16(21)14(9)18/h4,6,9H,5,7-8H2,1-3H3/t9-/m0/s1
• InChIKey: ABVRZQXICIZPLM-VIFPVBQESA-N
• SMILES: CC1COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCC(=O)C4(C)C

MAPK-IN-1 (Compound 2) is a MAPK signaling pathway inhibitor. MAPK-IN-1 exhibits AChE inhibitory activity with an IC50 of 23.84 μM. MAPK-IN-1 shows anti-neuroinflammatory and neuroprotective activity and can be used for Alzheimer’s disease research[1].
MAPK-IN-1 (Compound 2) inhibits NO, IL-1β, IL-6, and TNF-α release in BV-2 cells with IC50 values of 0.49 ± 0.17, 1.34 ± 0.21, 9.17 ± 0.17 and 8.17 ± 0.23 μM, respectively[1].
MAPK-IN-1 downregulates LPS-induced phosphorylation of JNK, ERK, and p38 in MAPK signaling pathway[1].
MAPK-IN-1 inhibits expressions of iNOS, COX-2, and TLR4 in LPS-induced BV-2 cells[1].

Reference

[1]. Wu JS, et al. The oxygenated products of cryptotanshinone by biotransformation with Cunninghamella elegans exerting anti-neuroinflammatory effects by inhibiting TLR 4-mediated MAPK signaling pathway. Bioorg Chem. 2020 Nov;104:104246.
 [Content Brief]